Share Price:

APNASPENAspen Pharmacare Hldgs14500-149 (-1.02%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Author: bpc

Aspen’s revenue increases 22% to R36 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the sixth largest generic company in the world, has announced excellent results for the year ended 30 June 2015. These results benefitted from the contribution of acquisitions concluded during the prior year. GROUP PERFORMANCE Revenue increased by 22% to R36.1 billion. Operating profit rose by 14% to R8.4 billion. Normalised headline earnings, being headline earnings adjusted for specific non-trading items, increased by 15% to R5.6 billion. Normalised headline earnings per share improved by 15% to 1 219 cents. Borrowings, net of cash, increased R0.2 billion to R30.0 billion. R2.5 billion of this arose from unfavourable relative foreign exchange rate movements. Group operating cash flows remained strong and cash generated from operating activities increased by 26% to R4.8 billion. A capital distribution of 216 cents per ordinary share was declared. Stephen Saad, Aspen Group Chief Executive said, “The excellent results were led by the International business which remained the largest contributor to the Group, delivering 49% of gross revenue. Sales in Asia jumped 39% to R1.3 billion due to a combination of organic growth and recent acquisitions led by strong advances in Japan. The results were achieved despite an unfavourable exchange rate environment affecting the Group’s principal trading currencies, particularly relative to the US Dollar, which resulted in a devaluing of revenue flows and an increase in cost of goods. INTERNATIONAL BUSINESS In the International business, revenue climbed 46% to R18.6 billion and operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), advanced 42% to R5.2 billion. The International business performance was assisted by the inclusion of the significant transactions completed during the prior year and contributed more than half of Group EBITA.  The disposal of the rights to commercialise the fondaparinux products (being Arixtra and the authorised generic thereof) in the United States to Mylan, for a consideration of USD 300 million, became effective during the first half of the 2015 financial year with the consequential loss of contribution. Revenue from customers in Europe and the Commonwealth of Independent States (“Europe CIS”) increased 45% to R10.5 billion.  Finished dose form pharmaceutical sales to healthcare providers comprised R6.9 billion of the total sales.  The acquisition in the second half of the year of Mono-Embolex, an anti-coagulant with almost all of its sales in Germany, further strengthened Aspen’s offering in this therapeutic area.  The largest part of the balance of the sales in the region was from active pharmaceutical ingredient (“API”) sales.  Relative weakness of the Europe CIS currencies to the Rand reduced reported revenue from this region. Sales to customers in Latin America (excluding Venezuela) grew 44% to R3.4 billion, supported by the infant nutritionals acquisition in the prior year.  Performance was constrained due to poor supply by contract manufacturers of certain key pharmaceutical products.  In Venezuela, sales to customers were up 143% to R2.7 billion.   The results in Venezuela have been influenced by the application of hyper inflationary accounting principles and a change in the rate of exchange applied in the translation of local currency results from the prior year. The net effect of these entries on EBITA is not significant. Sales to customers in the Rest of the World were down 10% to R1.6 billion, influenced by the disposal of the fondaparinux products for the United States to Mylan. Capital expenditure projects remain underway in the Netherlands at Aspen Oss (Netherlands) and in France at Aspen Notre Dame de Bondeville (“Aspen NDB”).  At Aspen Oss, the projects are focused on the repurposing of facilities and at Aspen NDB, the addition of a new pre-filled syringe filling line is well advanced. SOUTH AFRICAN BUSINESS Revenue in the South African business increased by 16% to R8.6 billion.  Private sector pharmaceutical sales improved 12% through a combination of organic growth and new product launches.  Public sector sales grew 14% led by demand under the antiretroviral (“ARV”) tender.  The consumer division raised revenue by 23% due to a strong performance from infant nutritionals, with Infacare making impressive gains in its share of this category.   Revenue from manufacturing for third parties also showed a good increase. The increase in the ARV tender revenue coupled with the ongoing weakening of the Rand relative to the US Dollar and high wage and energy cost inflation has placed pressure on EBITA margins. Expansion projects continued at the Port Elizabeth finished dosage form manufacturing site and at the API manufacturing site in Cape Town (“Fine Chemicals”).  In Port Elizabeth, the building of the high containment facility is nearing completion and manufacturing trials in the hormonal suite have commenced.  The packing facility upgrade is complete.  Construction of the additional specialist sterile manufacturing facility has commenced.  At Fine Chemicals, production is underway in certain of the newly constructed suites, while other parts of this expansion and upgrade project remain in progress. ASIA PACIFIC BUSINESS Revenue in the Asia Pacific business was 5% lower at R8.1 billion and EBITA declined by 10% to R1.7 billion.  In Australasia sales to customers were 8% lower at R7.2 billion.  The key focus areas of branded pharmaceuticals and infant nutritionals both showed positive growth.  This was, however, reversed by the effect of disposals as well as the termination of licenses and contract manufacturing arrangements in the second half of the prior financial year.  These were undertaken in accordance with the strategy to achieve greater focus in this business.  Cost of goods in Australia increased due to the weakening of the Australian Dollar against the US Dollar in which many input costs are denominated. Sales to customers in Asia accelerated by 39% to R1.3 billion through a combination of organic growth and recent acquisitions, led by strong advances in Japan. SUB-SAHARAN BUSINESS In Sub-Saharan Africa, revenue was 1% higher at R2.8 billion.  A disappointing performance from the GSK Aspen Healthcare for Africa Collaboration, which was hampered by supply problems, limited performance in the region.  Weakening in-market currencies contributed to narrowing margins and a reduction of 6% in EBITA to R313 million. PROSPECTS Strategically, the… Continue reading Aspen’s revenue increases 22% to R36 billion

Divestment of portfolio of branded and generic products to Strides entities

Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of approximately A$265 million (“the Australian Transaction”). The portfolio of products in the Australian Transaction comprises a generic pharmaceutical business together with certain branded pharmaceutical assets. This portfolio recorded revenue of A$106 million and a direct contribution to profit before tax of A$26 million for the year ended 30 June 2014. In a separate transaction, Aspen Global Incorporated (“AGI”), a company incorporated in Mauritius, has entered into an agreement with Strides Pharma Global Pte Limited (“Strides Singapore”), a company incorporated in Singapore, in terms whereof AGI will divest to Strides Singapore, a portfolio of six branded prescription products, for a consideration of approximately US$92 million. This portfolio recorded revenue of US$12 million and a direct contribution to profit before tax of US$10 million for the year ended 30 June 2014. Strides Australia and Strides Singapore are wholly owned subsidiaries of Strides Arcolab Limited (“Strides”), a pharmaceutical company headquartered and publicly listed in India. Strides have a key focus on the development and manufacture of IP-led, niche pharmaceuticals products. These transactions form part of Aspen’s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity. The transactions are conditional upon, inter alia, the approval of the Australian Foreign Investments Review Board.   Durban 21 May 2015 Sponsor: Investec Bank Limited   ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Group”)

Cautionary Announcement

Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the Company’s securities. Durban 14 May 2015 Sponsor                                                                         Investec Bank Limited

Divestment of South African Business Unit to Litha

Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has concluded a set of agreements with Litha Pharma (Pty) Ltd (“Litha”) (a wholly owned South African subsidiary of Endo International Plc) in terms which Pharmacare will divest a business unit which forms part of its pharmaceutical division to Litha for a consideration of approximately R1.6 billion (“the Transaction”). The business unit concerned has a product portfolio comprising injectables and established brands. This portfolio recorded revenue of R362 million and a direct contribution to profit before tax of R136 million for the year ended 30 June 2014. The Transaction forms part of Aspen’s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity. The Transaction is conditional upon, inter alia, the approval of the South African Competition Authorities. Durban 11 May 2015 Sponsor: Investec Bank Limited

Gauteng Premier’s visit to Aspen is set to boost export growth

Clayville, Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the 5th largest generic company in the world, earlier today hosted a delegation of over 30 government dignitaries at its manufacturing facility where specialised infant nutritional products are produced for local and export markets. The facility is unique in that it contains highly specialized spray dried capability which enables the manufacture of some of the continent’s leading Infant Milk Formula (IMF) brands such as Infacare, Infacare Gold and the S-26 range. Aspen recently acquired the S-26 portfolio from Nestlé. The delegation was led by Gauteng Premier David Makhura and the Minister of Agriculture, Forestry and Fisheries Senzeni Zokwana, and included Gauteng MEC for Health Qedani Mahlangu and Ekurhuleni Mayor Mondli Gungubele. Government expressed their approval of Aspen’s commitment to the enhancement of local manufacturing, which significantly contributes to provide for increased economic growth and export opportunities in the province. Aspen’s range of IMFs has been earmarked for strategic export markets such as sub-Saharan Africa (SSA) and China. Stephen Saad, Aspen Group Chief Executive reiterated the Group’s global expansion into various markets including Africa, Europe, South America and Asia. “Aspen has successfully created a business presence on 6 continents and our previously stated objective of increasing our footprint in the Asian and SSA markets is rapidly materializing. China is a key growth area for the Group and its burgeoning population offers significant export opportunities for our infant nutritional and other locally manufactured products”. Saad said that the Group remained committed to South African economic development through ongoing investment in its manufacturing facilities. A key component of the IMF is the base powder that is currently imported. There are however opportunities for local agro processing of the base powder which will build value linkages across communities, provide a much needed economic boost and also curtail raw manufacturing costs which will result in enhanced competitiveness in export markets. He announced that a further capex has been earmarked for investment at the Aspen Nutritionals site in Clayville in order to increase manufacturing capacity for export markets. The investment would however be dependent upon various factors including local supply, competitive pricing and the review of tariffs on imported blended powder. “Aspen Nutritionals is one of very few facilities that has invested in specialized spray dried technology required in the manufacture of powdered IMF. The quality of our products continues to meet the highest international accreditation standards, which has enabled us to significantly increase our export base”, added Saad. Stavros Nicolaou Aspen Senior Executive Strategic Trade said: “Aspen’s objectives are entirely consistent and complimentary to Premier Makhura’s ten point economic growth plan of the province, which include re-industrialisation of the economy, creation of decent employment and the establishment of strategic partnerships” Aspen’s efforts to develop strategic partnerships for the supply of base powder further promotes trade and investment and supports the growth of key identified economic sectors in that it facilitates environmental sustainability and the efficient use of existing resources.

Aspen opposes violent attacks directed at fellow African migrants

Statement by Stephen Saad, Group CEO, Aspen Pharmacare Holdings Ltd “Aspen” on the violent attacks directed at fellow African migrants living in South Africa Durban – Aspen, largest producer and supplier of medicines to our African continent, in the strongest terms condemns the shameful and senseless harassment and violence directed at fellow African migrants, in KwaZulu Natal, Alexandra and other parts of our country. At this time we join many millions in our country, our continent and indeed around the world in conveying our heartfelt condolences to the families of those who lost their loved ones. Our thoughts also go out to those who have lost property and belongings and have subsequently been displaced to camps and other locations around our country. Accordingly Aspen was a leading part of the consultative stakeholder meeting on migrant Xenophobia convened by President Zuma and the Government of the Republic at the end of this week. At this meeting, some of Aspen’s proposals on addressing our country’s growing drug and substance abuse, one of the root causes identified by our Government of the problem was highlighted. To this end, Aspen will continue working with our Government and other civic organisations in assisting those who have been displaced and lost their belongings. On this basis, Aspen has made available a donation to enable procurement of much needed medicines for the camps, in order to contain the outbreak of diseases that has the potential to intensify this human tragedy. Furthermore, Aspen has undertaken together with other stakeholders, including Government, the sporting fraternity to co-ordinate a symbolic friendly soccer match, in which various leaders and both African and South African soccer legends will unite and send a strong message against Xenophobia. The aim is to host this match in Alexandra, the site of the senseless murder of Mozambican national Ernest Sithole, who died wearing a Bafana Bafana wrist band. Legally based African migrants are an integral part of our society and constitute a key part of the diversity that is the unique tapestry of our country. Those African migrants contribute much needed skills and intellectual capital to our economy. We acknowledge their contribution and call on all South Africans, the overwhelming majority of whom condemn Xenophobia to work together to re-establish an environment of tolerance, where all communities co-exist in peace and harmony. We must ensure these attacks are never repeated again. In closing, we call on all South Africans to support efforts at condemning Xenophobia, upholding the rule of Law and accelerating economic transformation and reducing inequality, all important aspects in ensuring an end to these deplorable attacks.

GSK announces completion of the sale of half its stake in Aspen

GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds of approximately ZAR 10.5 billion. Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital. Simon Dingemans, GSK’s Chief Financial Officer, said: “GSK has a long and successful commercial partnership with Aspen and our investment in the company has grown in value significantly over time. As we continue to reshape the Group around our core franchises and drive the benefits from the Novartis transaction, optimizing our financial flexibility to invest behind these priorities is key. As a result we have decided now is the right time to realise further value from this successful relationship. We continue to believe in the strategy of Aspen and we remain committed to working together in the future.” The Board of Aspen has agreed that Mr David Redfern, recently appointed as GSK’s nominee director to replace Mr Abbas Hussain on the Board, will remain a director of Aspen. Durban 13 March 2015 Sponsor: Investec Bank Limited   ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 (“Aspen” or “the Company”)

Aspen’s half-year gross revenue surges by 47% to R19 billion

Aspen’s half-year gross revenue surges by 47% to R19 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world, has announced stellar results for the six months ended 31 December 2014, which have primarily been driven by its offshore businesses. GROUP PERFORMANCE Gross revenue increased by 47% to R19.0 billion. Operating profit rose by 50% to R4.3 billion. Net profit after tax and earnings per share each advanced 27% to R2.5 billion and 539 cents respectively. Normalised headline earnings, being headline earnings adjusted for specific non-trading items, increased by 22% to R2.6 billion. Normalised headline earnings per share improved by 22% to 569 cents. Borrowings net of cash reduced by R1.2 billion while cash generated from operating activities accelerated 128%. Stephen Saad, Aspen Group Chief Executive said, “We are pleased with the Group’s excellent performance. These results were underpinned by the expansion of our International business, which now contributes 46% to the Group’s gross revenue. The Nutritionals products have also made an increased contribution to the Group..” “The global pharmaceutical industry is experiencing a prevalence of restructuring and consolidation, which creates acquisitive opportunities. Aspen is well placed to participate in these and its proven capability to successfully execute complex multi-territory transactions makes Aspen a strong candidate for such opportunities,” said Saad INTERNATIONAL BUSINESS Revenue in the International business was 158% higher at R8.8 billion and performance was boosted by the inclusion of the significant transactions completed during the previous financial year. Revenue from the Europe CIS business climbed 229% to R5.1 billion from finished dose form pharmaceuticals and active pharmaceutical ingredient sales. Revenue in Latin America advanced 118% to R2.6 billion, largely driven by the recent infant milk formula acquisition, while sales to customers in the Rest of the World were up 36% to R0.9 billion. Capital expenditure projects are continuing at Aspen Oss in the Netherlands and at the French-based Aspen Notre Dame de Bondeville site. ASIA PACIFIC BUSINESS Revenue in the Asia Pacific region was 3% higher at R4.4 billion where the Nutritionals products led the way with strong double-digit growth. Sales to customers in Asia continued on an impressive growth trajectory, doubling to R0.6 billion.  SOUTH AFRICAN BUSINESS As the ongoing leading pharmaceutical manufacturer in the country, revenue in the South African business grew by 12% to R4.3 billion. Private sector pharmaceutical sales increased 10% through a combination of organic growth and new product launches. Sales in the public sector were flat. The consumer division raised revenue by 30%, led by the Nutritionals products with Infacare achieving an increase in its share of this category. The capital expenditure projects at the Port Elizabeth finished dose form manufacturing site and the Cape Town API manufacturing site are progressing well. SUB-SAHARAN BUSINESS In Sub-Saharan Africa, revenue improved by 5% to R1.5 billion. Margin improvement initiatives yielded positive results and lifted EBITA 12% to R210 million.     Issued by:         Shauneen Beukes, Shauneen Beukes Communications Tel: +27 (012) 661-8467 : Cell: +27 82 389 8900   Disclaimer We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate, “could”, “may”, “endeavor”, “prospects” and “project” and similar expressions are intended to identify such forward looking statements, but are not the exclusive means of identifying such statements. By their very nature, forward looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward looking statements will not be achieved. If one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward looking statements are discussed in each year’s annual report. Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of the Listings Requirements of the JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwise. All profit forecasts published in this report are unaudited.

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below:

Human Capital
Legal

Supply Chain

Treasury
Ethics & Compliance
Risk & Sustainability
Digital Technology

Tax